Showing results (181-190 of 194) with videos related to
Sort By:
Pageof 20
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
<i>BRCA1</i> secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Cassandra J Vandenberg, et al.Cancer Chemotherapy and Pharmacology|April 18, 2022
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancerJulia Manzo, Shannon Puhalla, Shalu Pahuja, et al.Lancet (London, England)|September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialRobert L Coleman, Amit M Oza, Domenica Lorusso, et al.Molecular Cancer|August 5, 2024
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Yifan Wang, et al.Journal of the National Cancer Institute|May 16, 2020
BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-AnalysisRoshni D Kalachand, Britta Stordal, Stephen Madden, et al.Cancer Discovery|June 8, 2017
Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaOlga Kondrashova, Minh Nguyen, Kristy Shield-Artin, et al.Nature Communications|May 4, 2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2017
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based OutreachGoli Samimi, Marcus Q Bernardini, Lawrence C Brody, et al.Cancer Research|October 25, 2013
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinomaBrandon Leonard, Steven N Hart, Michael B Burns, et al.The New England Journal of Medicine|September 29, 2019
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian CancerRobert L Coleman, Gini F Fleming, Mark F Brady, et al.Pageof 20